Varje dag samlar vi de senast publicerade vetenskapliga studierna om hampa, CBD och cannabis och sammanfattar kort vad var och en undersökte — på svenska och engelska. Alla länkar går till primärkällan (PubMed, Europe PMC eller ClinicalTrials.gov). Sammanfattningarna är neutrala beskrivningar av vad forskarna studerade, inte hälsopåståenden.
Quality by Design-Driven Formulation Development of Cannabidiol Orally Disintegrating Tablets.
Scientifica (Cairo) · 2026 · PubMed
Svenska: The development of cannabidiol (CBD) orally disintegrating tablets (ODTs) is effective in treating anxiety in a patient-friendly manner. The application of Quality by Design (QbD) enhances the efficiency and robustness of the pharmaceutical development of CBD ODTs.
A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes.
Int J Pharm · 2026 Aug 25 · PubMed
Svenska: Cannabidiol (CBD) has significant therapeutic potential, but its oral delivery remains limited by poor aqueous solubility, variable intestinal absorption, and extensive first-pass metabolism.
Distinguishing Medical From Nonmedical Cannabis Use Among US Young Adult Cancer Survivors.
Subst Use Addctn J · 2026 Aug 25 · PubMed
Svenska: Many young adults (YAs) who use cannabis use it both medically and nonmedically, which poses particular risks (eg, problematic use).
Exploring sex differences in endocannabinoid system biomarkers and their relationship with antidepressant treatment outcomes in major depressive disorder: a CAN-BIND 1 secondary analysis.
Eur Arch Psychiatry Clin Neurosci · 2026 Aug 25 · PubMed
Svenska: Sex differences in major depressive disorder (MDD) are well documented, but it remains unclear whether sex-related variation in peripheral endocannabinoid system (ECS)-related biomarkers is detectable in MDD.
Effects of Cannabidiol-Rich Cannabis Oil on Facial Expression Recognition and Theory of Mind in Children With Autism Spectrum Disorder: A Randomized Clinical Trial.
Autism Res · 2026 Aug 26 · PubMed
Svenska: To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)-rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD).
Cannabigerol improves MK-801-induced long-term recognition memory deficit in male rats through cortical TrkB-R signaling independently of changes in BDNF.
Pharmacol Biochem Behav · 2026 Aug 26 · PubMed
Svenska: Interest in the therapeutic potential of cannabigerol (CBG), a non-psychotomimetic cannabinoid derived from Cannabis sativa, has increased recently. However, preclinical studies examining its effects on cognitive impairment, a core symptom domain of schizophrenia, remain limited.
Acute effects of THC and a CBD+THC combination on cardiovascular haemodynamics and respiratory muscle activity during loaded breathing in healthy adults: A randomized placebo-controlled crossover study.
Br J Clin Pharmacol · 2026 Aug 27 · PubMed
Svenska: This study aimed to evaluate the acute effects of cannabidiol plus tetrahydrocannabinol (CBD+THC) and tetrahydrocannabinol (THC) oils on cardiovascular haemodynamics, respiratory muscle activity and peripheral tissue perfusion in healthy adults.
Next-generation hybrid nanosystems for cannabidiol: From molecular challenges to site-specific preclinical applications.
Biomed Pharmacother · 2026 Aug 27 · PubMed
Svenska: Cannabidiol (CBD) is a monoterpene phenolic compound extracted mainly from Cannabis sativa, which is produced in high amounts compared to other plants. The compound is regarded as a promising therapeutic agent with anti-inflammatory, analgesic, and neuroprotective effects for biomedical use.